Cargando…
Decreased Antibody Response After Severe Acute Respiratory Syndrome Coronavirus 2 Vaccination in Patients With Down Syndrome
: The risk of a severe course of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in adults with Down syndrome is increased, resulting in an up to 10-fold increase in mortality, in particular in those >40 years of age. After primary SARS-CoV-2 vaccination, the higher risks...
Autores principales: | , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9278229/ https://www.ncbi.nlm.nih.gov/pubmed/35748853 http://dx.doi.org/10.1093/infdis/jiac235 |
_version_ | 1784746147618750464 |
---|---|
author | Streng, Bianca M M Bont, Marin Delemarre, Eveline M Binnendijk, Rob S Smit, Gaby den Hartog, Gerco Coppus, Antonia M W de Vries, Esther Weijerman, Michel E Lamberts, Regina de Graaf, Gert van der Klis, Fiona R Vidarsson, Gestur Rave, Neele Bont, Louis J Wildenbeest, Joanne G |
author_facet | Streng, Bianca M M Bont, Marin Delemarre, Eveline M Binnendijk, Rob S Smit, Gaby den Hartog, Gerco Coppus, Antonia M W de Vries, Esther Weijerman, Michel E Lamberts, Regina de Graaf, Gert van der Klis, Fiona R Vidarsson, Gestur Rave, Neele Bont, Louis J Wildenbeest, Joanne G |
author_sort | Streng, Bianca M M |
collection | PubMed |
description | : The risk of a severe course of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in adults with Down syndrome is increased, resulting in an up to 10-fold increase in mortality, in particular in those >40 years of age. After primary SARS-CoV-2 vaccination, the higher risks remain. In this prospective observational cohort study, SARS-CoV-2 spike S1–specific antibody responses after routine SARS-CoV-2 vaccination (BNT162b2, messenger RNA [mRNA]–1273, or ChAdOx1) in adults with Down syndrome and healthy controls were compared. Adults with Down syndrome showed lower antibody concentrations after 2 mRNA vaccinations or after 2 ChAdOx1 vaccinations. After 2 mRNA vaccinations, lower antibody concentrations were seen with increasing age. CLINICAL TRIALS REGISTRATION: NCT05145348. |
format | Online Article Text |
id | pubmed-9278229 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Oxford University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-92782292022-07-18 Decreased Antibody Response After Severe Acute Respiratory Syndrome Coronavirus 2 Vaccination in Patients With Down Syndrome Streng, Bianca M M Bont, Marin Delemarre, Eveline M Binnendijk, Rob S Smit, Gaby den Hartog, Gerco Coppus, Antonia M W de Vries, Esther Weijerman, Michel E Lamberts, Regina de Graaf, Gert van der Klis, Fiona R Vidarsson, Gestur Rave, Neele Bont, Louis J Wildenbeest, Joanne G J Infect Dis Brief Report : The risk of a severe course of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in adults with Down syndrome is increased, resulting in an up to 10-fold increase in mortality, in particular in those >40 years of age. After primary SARS-CoV-2 vaccination, the higher risks remain. In this prospective observational cohort study, SARS-CoV-2 spike S1–specific antibody responses after routine SARS-CoV-2 vaccination (BNT162b2, messenger RNA [mRNA]–1273, or ChAdOx1) in adults with Down syndrome and healthy controls were compared. Adults with Down syndrome showed lower antibody concentrations after 2 mRNA vaccinations or after 2 ChAdOx1 vaccinations. After 2 mRNA vaccinations, lower antibody concentrations were seen with increasing age. CLINICAL TRIALS REGISTRATION: NCT05145348. Oxford University Press 2022-06-24 /pmc/articles/PMC9278229/ /pubmed/35748853 http://dx.doi.org/10.1093/infdis/jiac235 Text en © The Author(s) 2022. Published by Oxford University Press on behalf of Infectious Diseases Society of America. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (https://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com |
spellingShingle | Brief Report Streng, Bianca M M Bont, Marin Delemarre, Eveline M Binnendijk, Rob S Smit, Gaby den Hartog, Gerco Coppus, Antonia M W de Vries, Esther Weijerman, Michel E Lamberts, Regina de Graaf, Gert van der Klis, Fiona R Vidarsson, Gestur Rave, Neele Bont, Louis J Wildenbeest, Joanne G Decreased Antibody Response After Severe Acute Respiratory Syndrome Coronavirus 2 Vaccination in Patients With Down Syndrome |
title | Decreased Antibody Response After Severe Acute Respiratory Syndrome Coronavirus 2 Vaccination in Patients With Down Syndrome |
title_full | Decreased Antibody Response After Severe Acute Respiratory Syndrome Coronavirus 2 Vaccination in Patients With Down Syndrome |
title_fullStr | Decreased Antibody Response After Severe Acute Respiratory Syndrome Coronavirus 2 Vaccination in Patients With Down Syndrome |
title_full_unstemmed | Decreased Antibody Response After Severe Acute Respiratory Syndrome Coronavirus 2 Vaccination in Patients With Down Syndrome |
title_short | Decreased Antibody Response After Severe Acute Respiratory Syndrome Coronavirus 2 Vaccination in Patients With Down Syndrome |
title_sort | decreased antibody response after severe acute respiratory syndrome coronavirus 2 vaccination in patients with down syndrome |
topic | Brief Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9278229/ https://www.ncbi.nlm.nih.gov/pubmed/35748853 http://dx.doi.org/10.1093/infdis/jiac235 |
work_keys_str_mv | AT strengbiancamm decreasedantibodyresponseaftersevereacuterespiratorysyndromecoronavirus2vaccinationinpatientswithdownsyndrome AT bontmarin decreasedantibodyresponseaftersevereacuterespiratorysyndromecoronavirus2vaccinationinpatientswithdownsyndrome AT delemarreevelinem decreasedantibodyresponseaftersevereacuterespiratorysyndromecoronavirus2vaccinationinpatientswithdownsyndrome AT binnendijkrobs decreasedantibodyresponseaftersevereacuterespiratorysyndromecoronavirus2vaccinationinpatientswithdownsyndrome AT smitgaby decreasedantibodyresponseaftersevereacuterespiratorysyndromecoronavirus2vaccinationinpatientswithdownsyndrome AT denhartoggerco decreasedantibodyresponseaftersevereacuterespiratorysyndromecoronavirus2vaccinationinpatientswithdownsyndrome AT coppusantoniamw decreasedantibodyresponseaftersevereacuterespiratorysyndromecoronavirus2vaccinationinpatientswithdownsyndrome AT devriesesther decreasedantibodyresponseaftersevereacuterespiratorysyndromecoronavirus2vaccinationinpatientswithdownsyndrome AT weijermanmichele decreasedantibodyresponseaftersevereacuterespiratorysyndromecoronavirus2vaccinationinpatientswithdownsyndrome AT lambertsregina decreasedantibodyresponseaftersevereacuterespiratorysyndromecoronavirus2vaccinationinpatientswithdownsyndrome AT degraafgert decreasedantibodyresponseaftersevereacuterespiratorysyndromecoronavirus2vaccinationinpatientswithdownsyndrome AT vanderklisfionar decreasedantibodyresponseaftersevereacuterespiratorysyndromecoronavirus2vaccinationinpatientswithdownsyndrome AT vidarssongestur decreasedantibodyresponseaftersevereacuterespiratorysyndromecoronavirus2vaccinationinpatientswithdownsyndrome AT raveneele decreasedantibodyresponseaftersevereacuterespiratorysyndromecoronavirus2vaccinationinpatientswithdownsyndrome AT bontlouisj decreasedantibodyresponseaftersevereacuterespiratorysyndromecoronavirus2vaccinationinpatientswithdownsyndrome AT wildenbeestjoanneg decreasedantibodyresponseaftersevereacuterespiratorysyndromecoronavirus2vaccinationinpatientswithdownsyndrome |